CONTEXT: Complaints from hypoparathyroid patients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects of PTH therapy to ameliorate them. OBJECTIVE: We tested the hypothesis that PTH(1-84) therapy improves QOL in hypoparathyroidism. DESIGN: Fifty-four hypoparathyroid subjects received open-label recombinant human PTH(1-84). Before and during PTH(1-84), subjects completed the RAND 36-Item Health Survey, a measure of health-related QOL covering 8 domains of physical and mental health. RESULTS: At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.35 to -0.78; P < 0.001 for all). With PTH(1-84), the total score improved as early as month 1 and remained higher through 1 year (400 ± 200 to 478 ± 230; P = 0.001). The overall mental component summary score improved (204 ± 110 to 247 ± 130; P = 0.001), as did 3 mental health domains (vitality, social functioning, and mental health), all within 1 month (T-scores improving from -1.3 to -0.7, -1.0 to -0.6, and -0.9 to -0.3, respectively; P < 0.05 for all). The overall physical component summary score also increased by 1 month and remained higher at 1 year (196 ± 110 to 231 ± 130; P = 0.003) as did 2 physical health domains (physical functioning and general health: T-scores improving from -0.8 to -0.4, -1.2 to -0.8, respectively; P < 0.01 for both). CONCLUSIONS: These data suggest that hypoparathyroidism is associated with compromised QOL. Along with improved biochemical control, these results indicate that PTH(1-84) treatment of hypoparathyroidism improves physical and mental functioning.
CONTEXT: Complaints from hypoparathyroidpatients often reflect a reduction in quality of life (QOL), yet few data exist characterizing these complaints or the potential effects of PTH therapy to ameliorate them. OBJECTIVE: We tested the hypothesis that PTH(1-84) therapy improves QOL in hypoparathyroidism. DESIGN: Fifty-four hypoparathyroid subjects received open-label recombinant humanPTH(1-84). Before and during PTH(1-84), subjects completed the RAND 36-Item Health Survey, a measure of health-related QOL covering 8 domains of physical and mental health. RESULTS: At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.35 to -0.78; P < 0.001 for all). With PTH(1-84), the total score improved as early as month 1 and remained higher through 1 year (400 ± 200 to 478 ± 230; P = 0.001). The overall mental component summary score improved (204 ± 110 to 247 ± 130; P = 0.001), as did 3 mental health domains (vitality, social functioning, and mental health), all within 1 month (T-scores improving from -1.3 to -0.7, -1.0 to -0.6, and -0.9 to -0.3, respectively; P < 0.05 for all). The overall physical component summary score also increased by 1 month and remained higher at 1 year (196 ± 110 to 231 ± 130; P = 0.003) as did 2 physical health domains (physical functioning and general health: T-scores improving from -0.8 to -0.4, -1.2 to -0.8, respectively; P < 0.01 for both). CONCLUSIONS: These data suggest that hypoparathyroidism is associated with compromised QOL. Along with improved biochemical control, these results indicate that PTH(1-84) treatment of hypoparathyroidism improves physical and mental functioning.
Authors: John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders Journal: J Bone Miner Res Date: 2011-10 Impact factor: 6.741
Authors: Karen K Winer; Ninet Sinaii; James Reynolds; Donna Peterson; Karen Dowdy; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958
Authors: Rachel I Gafni; Jaime S Brahim; Panagiota Andreopoulou; Nisan Bhattacharyya; Marilyn H Kelly; Beth A Brillante; James C Reynolds; Hua Zhou; David W Dempster; Michael T Collins Journal: J Bone Miner Res Date: 2012-08 Impact factor: 6.741
Authors: Karen K Winer; Bo Zhang; Joseph A Shrader; Donna Peterson; Michaele Smith; Paul S Albert; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Wiebke Arlt; Christian Fremerey; Frank Callies; Martin Reincke; Peter Schneider; Wolfgang Timmermann; Bruno Allolio Journal: Eur J Endocrinol Date: 2002-02 Impact factor: 6.664
Authors: Kathryn H Chomsky-Higgins; Holly M Rochefort; Carolyn D Seib; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Insoo Suh Journal: World J Surg Date: 2018-02 Impact factor: 3.352
Authors: John P Bilezikian; Maria Luisa Brandi; Natalie E Cusano; Michael Mannstadt; Lars Rejnmark; René Rizzoli; Mishaela R Rubin; Karen K Winer; Uri A Liberman; John T Potts Journal: J Clin Endocrinol Metab Date: 2016-03-03 Impact factor: 5.958